LENZ Therapeutics, Inc. (LENZ) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 4.99 |
| Open | 4.99 |
| Day High | 4.99 |
| Day Low | 4.68 |
| 52-Week High | 50.4 |
| 52-Week Low | 4.68 |
| Volume | 1.94M |
| Average Volume | 880,411 |
| Market Cap | 153.01M |
| PE | -1.36 |
| EPS | -3.6 |
| Moving Average 50 Days | 6.83 |
| Moving Average 200 Days | 16.87 |
| Change | -0.11 |
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia
GlobeNewswire Inc.
Mar 10, 2026 12:00 PM GMT
MAA submission to the European Medicines Agency represents a key regulatory milestone in LENZ’s strategy to expand global access to VIZZ Submission of MAA in Europe results in the fifth ex-U.S. regulatory submission for VIZZ SAN DIEGO, March 10, 202
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
GlobeNewswire Inc.
Jan 14, 2026 1:30 PM GMT
Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours The “Make it VIZZable” campaign features SJP enjoying the everyday convenience of clear near vision
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
GlobeNewswire Inc.
Jan 07, 2026 10:08 PM GMT
Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 Achieved approximately $1.6 million in net product revenue with over 20,000 prescriptions fill